

“A Pilot Phase 2 Randomized Trial to Evaluate the Safety and Potential Efficacy of Etravirine in Friedreich Ataxia Patients”

Table S1. Overall and by dose average outcome measures scores.

	T-4	T0	T2	T4	T+4	p.value*
Peak VO ₂	13.87 (3.08)	14.55 (3.36)		15.51 (3.20)	14.35 (2.88)	0.004
<i>dose 200</i>	14.19 (2.75)	13.97 (3.26)		14.77 (3.29)	13.78 (2.95)	0.433
<i>dose 400</i>	13.55 (3.44)	15.14 (3.45)		16.25 (3.02)	14.95 (2.77)	0.001
SARA	20.71 (8.19)	21.16 (8.52)	20.26 (8.83)	20.03 (9.05)	21.32 (8.52)	<0.001
<i>dose 200</i>	20.03 (8.23)	20.38 (8.69)	19.65 (8.88)	19.41 (9.22)	20.35 (8.70)	0.003
<i>dose 400</i>	21.38 (8.35)	21.94 (8.54)	20.88 (9.00)	20.65 (9.12)	22.34 (8.49)	<0.001
Peak W	20.44 (6.96)	20.29 (5.95)		23.24 (7.17)	22.12 (6.69)	0.007
<i>dose 200</i>	21.24 (7.71)	19.29 (4.95)		22.00 (6.16)	21.29 (5.52)	0.152
<i>dose 400</i>	19.65 (6.25)	21.29 (6.82)		24.47 (8.05)	23.00 (7.83)	0.013
Septal wall thickness	11.84 (1.94)	12.01 (1.92)		12.12 (2.05)	12.26 (1.93)	0.232
<i>dose 200</i>	12.21 (2.09)	12.15 (2.12)		12.21 (2.13)	12.12 (1.97)	0.965
<i>dose 400</i>	11.47 (1.76)	11.88 (1.75)		12.03 (2.03)	12.41 (1.93)	0.064
Sokolow-Lyon index	18.55 (9.66)	18.44 (7.93)		16.85 (7.51)	18.64 (8.04)	0.099
<i>dose 200</i>	19.69 (11.29)	18.29 (8.26)		16.29 (7.56)	17.94 (8.00)	0.100
<i>dose 400</i>	17.41 (7.90)	18.58 (7.83)		17.41 (7.64)	19.38 (8.28)	0.092

* P-values were obtained from One Way ANOVA.